Tofacitinib
Tofacitinib is a small-molecule Janus kinase inhibitor targeting JAK1 and JAK3 with some activity against JAK2, blocking the downstream signal transducer and activator of transcription (STAT) pathways.
Tofacitinib is a small-molecule Janus kinase inhibitor targeting JAK1 and JAK3 with some activity against JAK2, blocking the downstream signal transducer and activator of transcription (STAT) pathways. That pairing matters mechanistically: JAK3 associates exclusively with the common gamma chain, so inhibiting the JAK1/JAK3 combination shuts down the interleukin-2, -4, -7, -9, -15 and -21 signals that drive lymphocyte activation, while tofacitinib-mediated JAK2 inhibition accounts for the anemia and cytopenias seen at higher exposure, since JAK2 carries erythropoietin and thrombopoietin signaling. Classified under ATC code L04, it was among the first oral JAK inhibitors approved for clinical use, a targeted immunotherapy that interrupts JAK/STAT-mediated cytokine signaling — including pathways driven by proinflammatory interleukins and interferons — suppressing the immune activation central to immune-mediated inflammatory diseases. Being a small molecule with a short half-life given twice daily, it differs practically from biologics such as adalimumab, etanercept and rituximab, which are injected, act on a single extracellular target, and persist for weeks: JAK inhibition can be stopped quickly when infection appears, but covers many cytokines at once rather than one.
It is approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis (UC), and has been investigated off-label across numerous dermatologic and inflammatory conditions, including ankylosing spondylitis. As a first-generation agent it sits alongside newer, more selective ones such as upadacitinib, baricitinib, abrocitinib and deucravacitinib.
Its safety profile has shaped the entire class. A post-authorization trial in rheumatoid arthritis patients over 50 with a cardiovascular risk factor, comparing tofacitinib against Tnf inhibitors, found higher rates of major adverse cardiovascular events and malignancy — the basis of boxed warnings now applied across JAK inhibitors, alongside serious infection and thrombosis. Herpes zoster reactivation is characteristic and notably more frequent than with biologics. The findings have restricted use in many settings to patients who have failed a Tnf inhibitor, and continue to drive real-world safety research.
Where the papers sit
16 papers from the last 6 months study tofacitinib directly · updated from PubMed 12 Oct 2026
Study type 1 clinical trial · 8 observational · 1 human data · 6 preclinical
Themes 3 themes · 1 paradigm shift
-
JAK Inhibition in Rheumatoid Arthritis
JAK inhibition in rheumatoid arthritis is being assessed beyond joint response, with attention to lipids, cardiometabolic effects, endothelial function and treatment persistence. Tofacitinib and other JAK inhibitors alter SOCS signalling, immunoproteasome activity, and T-cell activation and metabolism. Real-world studies continue to compare monotherapy, csDMARD combinations and biologic alternatives while identifying reasons for discontinuation. Sustained-release delivery and dose-response work point toward longer-acting, more individualized treatment, but clinical trade-offs remain unresolved.
9 papers · 56.2%
-
JAK Inhibitors in Alopecia Areata
JAK inhibitors are being compared for alopecia areata across acute, chronic and long-standing disease, using SALT response and treatment safety as key endpoints. Tofacitinib, baricitinib and Ritlecitinib show the field moving toward agent selection by disease duration and severity rather than a single universal regimen. Real-world cohorts also highlight tolerability issues such as acne. Durability of regrowth and comparative effectiveness outside trials remain open questions.
3 papers · 18.8%
-
Others — Tofacitinib in Colitis and Formulation
Tofacitinib development here divides between oral formulation optimization and clinical treatment of inflammatory bowel disease. Tablet studies target pH-independent release, comparative dissolution and pharmacokinetics, including extended-release approaches. Clinical work evaluates induction in chronic pouchitis and compares effectiveness and safety with filgotinib and upadacitinib in ulcerative colitis. These strands share the drug but not a single biological question or clear common direction.
4 papers · 25%
Tofacitinib-associated treatment response in alopecia areata is strongly constrained by disease chronicity
The long-standing alopecia areata cohort and the acute-versus-nonacute alopecia areata cohort both challenge the assumption that JAK inhibition produces broadly comparable responses across alopecia areata. Instead, the long-standing cohort found limited overall benefit, frequent discontinuation for lack of efficacy, and only a subset achieving substantial regrowth, while the comparative cohort found markedly better outcomes in acute disease than in nonacute disease and identified tofacitinib treatment as a predictor of super-response. Together, these findings make disease duration and treatment history central determinants of response rather than incidental clinical modifiers, narrowing the circumstances in which tofacitinib can be expected to work well 42377046Jun 42186168May.
Papers
The 16 papers from the last 6 months that study tofacitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
JAK Inhibition in Rheumatoid Arthritis (9)
- Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. Arthritis research & therapy · 16 Sept 2026 PMID 42745343
- Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). Clinical rheumatology · 19 Aug 2026 PMID 42616227
- Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study. Clinical rheumatology · 13 Aug 2026 PMID 42587227
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
- Deciphering in vitro-in vivo correlation of single-dose injectable sustained-release tofacitinib-loaded microspheres for long-acting anti-inflammatory therapy of rheumatoid arthritis. International journal of pharmaceutics · 27 Jul 2026 PMID 42508508
- Evaluating the cardiometabolic impact of Janus-kinase inhibition: An experimental analysis of Tofacitinib's therapeutic potential in a rodent model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jul 2026 PMID 42497584
- Exploring the dosage-effect relationship and mechanism of Huangqi in Huangqi Guizhi Wuwu decoction for treating rheumatoid arthritis based on the compatibility of the formula. Journal of ethnopharmacology · 14 May 2026 PMID 42134500
- Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort. British journal of clinical pharmacology · 8 May 2026 PMID 42101259
- JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 5 May 2026 PMID 42084739
JAK Inhibitors in Alopecia Areata (3)
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study. Acta dermato-venereologica · 30 Jun 2026 PMID 42377046
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. Acta dermato-venereologica · 26 May 2026 PMID 42186168
- Real-World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi-Center Cohort Study. Clinical and translational science · 21 Apr 2026 PMID 42012333
Others — Tofacitinib in Colitis and Formulation (4)
- Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial. BMJ open · 17 Jul 2026 PMID 42468955
- Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. Advances in therapy · 9 May 2026 PMID 42105145
- Development and Evaluation of Tofacitinib Tablets with Comparative Dissolution and Pharmacokinetic Studies in Beagle Dogs. AAPS PharmSciTech · 6 May 2026 PMID 42091763
- Investigation of the effects of organic acids on pH-independent drug release from extended-release hydrophilic matrix tablets: A case study with tofacitinib. Journal of pharmaceutical sciences · 19 Apr 2026 PMID 42002148
By study type
Clinical trials (1)
- Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial. BMJ open · 17 Jul 2026 PMID 42468955
Observational studies and case reports (8)
- Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. Arthritis research & therapy · 16 Sept 2026 PMID 42745343
- Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study). Clinical rheumatology · 19 Aug 2026 PMID 42616227
- Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study. Clinical rheumatology · 13 Aug 2026 PMID 42587227
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study. Acta dermato-venereologica · 30 Jun 2026 PMID 42377046
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. Acta dermato-venereologica · 26 May 2026 PMID 42186168
- Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. Advances in therapy · 9 May 2026 PMID 42105145
- Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort. British journal of clinical pharmacology · 8 May 2026 PMID 42101259
- Real-World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi-Center Cohort Study. Clinical and translational science · 21 Apr 2026 PMID 42012333
Human data, design not indexed (1)
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
Preclinical: animal, cell and lab studies (6)
- Deciphering in vitro-in vivo correlation of single-dose injectable sustained-release tofacitinib-loaded microspheres for long-acting anti-inflammatory therapy of rheumatoid arthritis. International journal of pharmaceutics · 27 Jul 2026 PMID 42508508
- Evaluating the cardiometabolic impact of Janus-kinase inhibition: An experimental analysis of Tofacitinib's therapeutic potential in a rodent model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 24 Jul 2026 PMID 42497584
- Exploring the dosage-effect relationship and mechanism of Huangqi in Huangqi Guizhi Wuwu decoction for treating rheumatoid arthritis based on the compatibility of the formula. Journal of ethnopharmacology · 14 May 2026 PMID 42134500
- Development and Evaluation of Tofacitinib Tablets with Comparative Dissolution and Pharmacokinetic Studies in Beagle Dogs. AAPS PharmSciTech · 6 May 2026 PMID 42091763
- JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 5 May 2026 PMID 42084739
- Investigation of the effects of organic acids on pH-independent drug release from extended-release hydrophilic matrix tablets: A case study with tofacitinib. Journal of pharmaceutical sciences · 19 Apr 2026 PMID 42002148
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.